Trisenox(arsenic trioxide)
Trisenox (arsenic trioxide) is a small molecule pharmaceutical. Arsenic trioxide was first approved as Trisenox on 2000-09-25. It is used to treat promyelocytic leukemia acute in the USA. It has been approved in Europe to treat promyelocytic leukemia acute.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
Trade Name
FDA
EMA
Trisenox (generic drugs available since 2018-08-31)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Arsenic trioxide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TRISENOX | Cephalon | N-021248 RX | 2017-10-13 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| arsenic trioxide | ANDA | 2023-05-04 |
| trisenox | New Drug Application | 2020-10-21 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
ARSENIC TRIOXIDE, TRISENOX, CEPHALON | |||
| 2025-01-12 | ODE-167 | ||
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9017 | Injection, arsenic trioxide, 1 mg |
Clinical
Clinical Trials
126 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Plasma cell neoplasms | D054219 | 5 | 8 | — | — | — | 11 | ||
| Multiple myeloma | D009101 | C90.0 | 3 | 5 | — | — | — | 7 | |
| Lymphoma | D008223 | C85.9 | 3 | 4 | — | — | — | 6 | |
| Neoplasms | D009369 | C80 | 2 | 3 | — | — | — | 5 | |
| Central nervous system neoplasms | D016543 | 3 | 2 | — | — | — | 4 | ||
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 1 | — | — | 1 | 2 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | 1 | — | — | 1 | 2 | |
| Neuroblastoma | D009447 | EFO_0000621 | — | 2 | — | — | — | 2 | |
| Basal cell carcinoma | D002280 | 2 | 1 | — | — | — | 2 | ||
| Myeloid leukemia | D007951 | C92 | 1 | 2 | — | — | — | 2 |
Show 28 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Primary myelofibrosis | D055728 | D47.4 | 2 | — | — | — | — | 2 | |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | — | — | — | — | 1 |
| Non-small-cell lung carcinoma | D002289 | 1 | — | — | — | — | 1 | ||
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | 1 | — | — | — | — | 1 | |
| Essential thrombocythemia | D013920 | D47.3 | 1 | — | — | — | — | 1 | |
| Polycythemia vera | D011087 | D45 | 1 | — | — | — | — | 1 | |
| Gata2 deficiency | D000077428 | 1 | — | — | — | — | 1 | ||
| Melanoma | D008545 | 1 | — | — | — | — | 1 | ||
| Glioblastoma | D005909 | EFO_0000515 | 1 | — | — | — | — | 1 | |
| Gliosarcoma | D018316 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Coronary disease | D003327 | — | — | — | — | 2 | 2 | ||
| Acute coronary syndrome | D054058 | EFO_0005672 | — | — | — | — | 2 | 2 | |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | — | — | 2 | 2 |
| Non-hodgkin lymphoma | D008228 | C85.9 | — | — | — | — | 1 | 1 | |
| B-cell lymphoma marginal zone | D018442 | C88.4 | — | — | — | — | 1 | 1 | |
| Prolymphocytic leukemia | D015463 | — | — | — | — | 1 | 1 | ||
| Follicular lymphoma | D008224 | C82 | — | — | — | — | 1 | 1 | |
| Waldenstrom macroglobulinemia | D008258 | C88.0 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ARSENIC TRIOXIDE |
| INN | — |
| Description | Arsenic trioxide, sold under the brand name Trisenox among others, is an inorganic compound with the formula As2O3. As an industrial chemical, its major uses include the manufacture of wood preservatives, pesticides, and glass. It is also used as a medication to treat a type of cancer known as acute promyelocytic leukemia. For this use it is given by injection into a vein.
|
| Classification | Small molecule |
| Drug class | Antineoplastic agent |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | O1[As]2O[As]3O[As]1O[As](O2)O3 |
Identifiers
| PDB | — |
| CAS-ID | 1327-53-3 |
| RxCUI | 18330 |
| ChEMBL ID | CHEMBL2362016 |
| ChEBI ID | 30621 |
| PubChem CID | 261004 |
| DrugBank | DB01169 |
| UNII ID | — |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 11,844 documents
View more details
Safety
Black-box Warning
Black-box warning for: Arsenic trioxide, Trisenox
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
10,260 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more